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Introduction
Stroke is a leading cause of morbidity and mortality, whose prev-
alence increases dramatically with age. Despite its substantial 
heritable basis, only a small number of causative genes have 
so far been identified, generally for severe early-onset pheno-
types (cerebral autosomal dominant or recessive arteriopathy 
with subcortical infarcts and leukoencephalopathy: CADASIL 
[NOTCH3], CARASIL [HTRA1], and porencephaly [COL4A1]) 
(1–3). Such cases have revealed important pathways that contrib-
ute to stroke, including the roles of Notch and TGF-β signaling. 
In the same way, the vascular basement membrane’s contribu-
tion (COL4A1 and COL4A2) (3, 4) to juvenile stroke phenotypes 
further stimulated investigation of the cellular components 
(endothelial and mural cells) upon which brain vascular integ-
rity depends. The demonstration that Notch signaling regu-
lates pericyte numbers (5, 6) has in turn provided a mechanistic 
explanation for disorders such as CADASIL. These examples of 
juvenile stroke resulting from severe alterations in brain vascular 
development raise the intriguing possibility that milder changes 
contribute to late-onset disease and that a larger proportion of 
strokes have embryonic origins. It is therefore notable that the 
same genes regulate cerebral structural development and angio-
genesis (7) and that the cell populations essential for cerebral 
vascular homeostasis (pericytes and vascular smooth muscle) 
are predominantly derived from the neural crest (8, 9).
The increasing prevalence of stroke exerts disproportionately 
severe effects on the quality of life of affected individuals and their 
families. Consequently, phenotypes predictive of future stroke 
merit investigation, with the goal of developing treatments tar-
geting causative pathways and preventing a frequently pretermi-
nal disease. One such phenotype is cerebral small-vessel disease 
(CSVD), which represents a major risk factor for both ischemic 
and hemorrhagic stroke (10–13). Characterized by perturbed per-
forating end-artery function, CSVD results in lesions apparent 
on MRI that encompass white matter hyperintensities (WMHs), 
dilated perivascular spaces, microbleeds, and lacunar infarcts. 
These markers of cerebrovascular pathology provide opportuni-
ties for gene discovery and for defining the mechanisms that con-
tribute to subsequent stroke.
Our study evaluated the hypothesis that the forkhead box 
transcription factor FOXC1, which patterns multiple organs 
including the CNS, contributes to CSVD. It was prompted by a 
higher incidence of self-reported stroke in some of our local ped-
igrees with FOXC1 mutations and supported experimentally by: 
(a) blood-stained hydrocephalus in murine Foxc1–/– mutants, (b) 
related zebrafish foxc1 morphant phenotypes, and (c) the exten-
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Genomic Epidemiology (CHARGE) consortium. This identified 
10 WMH-associated SNPs (P = 0.0031–0.048, Bonferroni-cor-
rected) located in an intron of GMDS, which catalyzes GDP-man-
nose metabolism and lies adjacent to FOXC1 (Figure 1A and Sup-
plemental Table 1; supplemental material available online with 
this article; doi:10.1172/JCI75109DS1). Analysis of 2 independent 
expression quantitative trait loci (eQTL) datasets (19, 20) demon-
strated that 3 of these WMH-associated SNPs strongly influence 
FOXC1 transcript levels (study 1: P = 2.96 × 10–8–5.82 × 10–11; study 
2: P = 0.01–0.008; Supplemental Table 1).
We next assessed whether patients with FOXC1-attributable 
ARS exhibited CSVD. Eighteen patients with either a FOXC1 
mutation or copy number variation (CNV) (comprising missense 
sive involvement of Foxc1 in vascular development (14–16). The 
latter encompasses essential roles in arterial specification, angio-
genesis regulation, endothelial lymphatic cell sprouting (17), as 
well as a requirement for Foxc1 in brain pericytes (18). Here, we 
demonstrate  a role for FOXC1 in cerebrovascular disease through 
targeted genome-wide association (GWA) analysis, MRI of glau-
coma patients with FOXC1-attributable Axenfeld-Rieger syn-
drome (ARS), and detailed zebrafish analyses.
Results and Discussion
We first performed a meta-analysis of GWA data for 500 kb 
encompassing FOXC1 on 6p25 in 9,361 individuals with brain 
MRI data from the Cohorts for Heart and Aging Research in 
Figure 1. Aberrant FOXC1 function causes 
CSVD in patients and cerebral hemorrhage 
in zebrafish. (A) Regional association 
plot (meta-analysis, CHARGE consortium) 
displaying linkage disequilibrium between 
the 10 SNPs with WMH. (B) Diagrammatic 
representation of the missense or nonsense 
FOXC1 mutations or CNV extent for the 18 
patients imaged. (C–H) MRIs of patients with 
FOXC1 mutation (C–F), 6p25 deletion (G), and 
6p25 duplication (H) displaying WMH (arrow), 
dilated perivascular spaces (arrowhead), and 
lacunar infarct (asterisk). (I and J) Injection 
of 2 ng of foxc1a morpholino (MO) and 2 ng 
of foxc1b morpholino resulted in cerebral 
hemorrhage (arrow) at 48 hpf compared 
with injection of equimolar amounts of 5-bp 
mismatched morpholinos. Overexpression of 
foxc1a mRNA (75 pg) caused cerebral hemor-
rhage (K). Scale bars: 200 μm.
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pathway in foxc1 morphants. We observed reduced expression of 
both receptor tyrosine kinases (pdgfra and pdgfrb) in foxc1 mor-
phants (Figure 2, A–H), positioning Pdgf signaling genetically 
downstream of Foxc1. Importantly, the prevalence of cerebral 
hemorrhage induced by morpholino inhibition of pdgfra alone, or 
pharmacological inhibition of pdgfra and pdgfrb, synergized with 
foxc1 morpholino inhibition (Figure 2, I–L). This is consistent with 
a model in which Foxc1 regulates vascular stability through the 
Pdgfrαα homodimer and Pdgfrαβ heterodimer, either by the con-
trol of pdgfra and pdgfrb expression or indirectly as a consequence 
of aberrant neural crest migration and/or survival.
Since loss of neural crest–specific Pdgfra induces murine cere-
bral hemorrhage and irregular vascular smooth muscle cell cov-
erage (25, 26), we predicted loss of such cells in foxc1 morphants. 
In keeping with the aberrant cerebral neural crest migration and 
increased cell death (Supplemental Figure 4), foxc1 morphants 
exhibited reduced numbers of neural crest cells associating with 
the cerebral vasculature at 32 hours post fertilization (hpf) (foxc1MO 
1.6 ± 0.5, WT 2.2 ± 0.4; P = 0.0008) (Figure 3, A–C). Consistently, at 
4 days post fertilization (dpf), this manifested as reduced numbers 
of vascular smooth muscle cells (foxc1MO 48 ± 10, WT 61 ± 9; P = 0.01) 
(Figure 3, D–F). In contrast, we found that expression of markers for 
other vascular components (col4a1 and claudin5b) and endothelial 
cell numbers in both morphants and murine endothelial–specific 
Foxc1–/– mutants was unaltered (Supplemental Figure 5). Together, 
these data support a model of reduced neural crest–derived smooth 
[n = 4] or frameshift mutation [n = 3], segmental deletion [n = 5], 
or duplication [n = 6]) (Figure 1B) were recruited for cerebral MRI 
(Supplemental Table 2). All 18 displayed CSVD, including WMH, 
dilated perivascular spaces, and lacunar infarcts (Figure 1, C–H, 
Supplemental Figure 1, and Supplemental Table 2). These changes, 
present in patients as young as 1 year of age, reveal a developmen-
tal component to CSVD. Cerebrovascular phenotypes were evi-
dent with both 6p25 segmental duplication or deletion, demon-
strating that deviations from normal FOXC1 gene dosage result in 
similar anomalies, as previously observed with FOXC1-dependent 
cerebellar maldevelopment (21), corneal neovascularization (22), 
and ARS (23, 24). The 7 patients with coding mutations unambig-
uously demonstrate that impaired FOXC1 function alone is suffi-
cient to induce CSVD.
Consistent with these data, overexpression of zebrafish foxc1a 
or dual suppression of both paralogs (foxc1a and foxc1b) results in 
cerebral hemorrhage (overexpression 32 of 111 [28.8%], suppres-
sion 111 of 352 [31.5%]; Figure 1, I–K, and Supplemental Table 3). 
Notably, acellular perivascular spaces were evident on electron 
microscopy of foxc1 morpholino oligonucleotide–treated embryos 
(foxc1 morphants) (Supplemental Figure 2). Foxc1 was expressed 
in the neural crest, and in morphants, there was aberrant migra-
tion of the cerebral neural crest from which most mural cells are 
derived (Supplemental Figures 3 and 4). Since platelet-derived 
growth factor (PDGF) signaling regulates neural crest recruit-
ment to the developing vasculature, we evaluated this candidate 
Figure 2. Foxc1 regulates Pdgf signaling. Transcripts for pdgfra (Pdgfrα) and pdgfrb (Pdgfrβ) were expressed in neural crest cells at 20 hpf (arrows) in WT 
embryos (A and C) and were highly downregulated in foxc1 morphants (B and D). At 48 hpf, expression of pdgfra was observed in major cerebral blood 
vessels and ventral head mesenchyme (E, arrow), with the latter being reduced in foxc1 morphants (F), whereas pdgfrb expression was unaltered (G and H). 
A genetic interaction was observed between subthreshold inhibition of foxc1 and pdgfra (I) or with treatments that affected both Pdgfrα and Pdgfrβ sig-
naling, including dual-morpholino suppression (K) and the pan-Pdgfr inhibitor crenolanib (L). No interaction was observed using subthreshold inhibition of 
foxc1 and pdgfrb alone (J). Scale bar: 200 μm.
Downloaded from http://www.jci.org on February 13, 2015.   http://dx.doi.org/10.1172/JCI75109
The Journal of Clinical Investigation B r i e f  r e p o r t
4 8 8 0 jci.org   Volume 124   Number 11   November 2014
(18), reveal the contribution from altered neural crest function 
and substantially increase the proportion of strokes known to have 
developmental origins. Furthermore, the evidence presented 
here from Foxc1 and Pitx2 implicates other transcription factors 
with neural crest roles as candidates and thus provides practical 
opportunities for accelerating the identification of the molecular 
basis for stroke through integrated human genetic and zebrafish 
analyses. Our observation of a predominantly mural role for Foxc1 
in the cerebral vasculature, which contrasts with an endothelial 
cell contribution systemically (16), also merits investigation and 
may correlate with the unique endothelial barrier properties of 
the cerebral circulation. From a clinical perspective, the substan-
tial interval that elapses between the onset of MRI-detectable 
features of CSVD and the occurrence of stroke provides a ther-
apeutic window for intervention, and potentially, patients with 
mutations involving neural crest genes may benefit from common 
stroke-prevention strategies. Finally, our findings have direct 
implications for Axenfeld-Rieger syndrome, a glaucoma subtype 
frequently associated with progressive visual decline despite sur-
gical control of intraocular pressure (30). Evidence of a cerebral 
vasculopathy raises the possibility that perturbed vascular func-
tion contributes to the visual loss that has previously been attrib-
uted to optic nerve disease.
muscle cell coverage, impairing vascular stability (27), as a key com-
ponent of foxc1 morphants’ hemorrhagic phenotype.
To test the hypothesis that other ocular developmental genes 
with neural crest roles contribute to CSVD, we analyzed regional 
GWA data for PITX2, a neural crest–expressed, ARS-causing 
transcription factor that physically interacts with FOXC1. PITX2 
is associated with atrial fibrillation (28) and cardioembolic stroke 
(29), with the latter attributed to  cardiac arrhythmia. Nine SNPs 
within a 500-kb PITX2-encompassing interval were significantly 
associated with WMH (P = 0.0071–0.022, Bonferroni-corrected; 
Supplemental Table 4 and Supplemental Figure 6, and MRIs of 
young PITX2-attributable ARS patients revealed CSVD (Figure 3, 
G and H). Thus, PITX2 may increase stroke risk independently 
of atrial fibrillation. Consistent with such a primary alteration to 
cerebral vasculature, murine Pitx2–/– mutants exhibited reduced 
and discontinuous smooth muscle actin staining of cerebral ves-
sels (Figure 3, I and J) as well as increased cerebral vessel density 
(Pitx2–/– 12.2 ± 0.8, WT 9.3 ± 1.0; P = 0.04).
By demonstrating that aberrant FOXC1 function causes 
human cerebrovascular disease, this study extends the knowledge 
of disorders whose genetic etiology remains largely unexplained. 
Our data from patients and zebrafish models, coupled with 
another laboratory’s detailed analysis of murine Foxc1 mutants 
Figure 3. foxc1 and PITX2 regulate vascular smooth muscle cell numbers. Number of sox10-positive neural crest cells that associated with the cerebral 
vasculature in WT embryos at 32 hpf (A) was significantly reduced in foxc1 morphants (B and C). Cerebral vascular mural cells expressed smooth muscle actin 
by 4 dpf (D), with fewer smooth muscle actin–positive cells observed in foxc1 morphants (E and F). Patients with PITX2-attributable ARS exhibited CSVD: 
(G) WMH, (arrows) and (H) dilated perivascular spaces (arrowheads). Compared with WT embryos (I), murine Pitx2–/– mutants demonstrated reduced and 
discontinuous smooth muscle actin staining of large and small cerebral vessels (J). Original magnification, ×200 (A and B), ×100 (D and E), and ×400 (I and J).
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Methods
Statistics. GWA data are presented as the –logP value, with Bonferroni’s 
correction for the number of independent comparisons determined 
via the number of linkage disequilibrium blocks. For analysis of cell 
numbers and genetic interactions, unpaired 2-tailed Student’s t tests 
were used to assess significance. Analyses are displayed graphically 
as the mean ± SEM. All experiments were conducted in triplicate. A 
P value of less than 0.05 was considered statistically significant.
Study approval. Ethical approval was provided by the University 
of Alberta Health Research Ethics Board, with written informed con-
sent received from all participants prior to their inclusion in the study. 
Animal experiments were approved by the IACUC of the University 
of Alberta, the University of Michigan, and Northwestern University.
Further details regarding the methods are available in the Sup-
plemental Methods.
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